Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A fast-acting acid blocker called tegoprazan significantly reduced heartburn in patients with non-erosive reflux disease (NERD), the most common form of GERD. A phase III trial found up to 74% improvement in heartburn-free days over placebo. A separate smaller trial also found tegoprazan eased erosive esophagitis symptoms faster than a standard PPI, though healing rates were similar at 4 weeks.
Tegoprazan, a novel potassium-competitive acid blocker (P-CAB), is showing real promise for patients with gastroesophageal reflux disease (GERD) — particularly those with non-erosive reflux disease (NERD), the most common form of the condition. A phase III trial (TRIUMpH-NERD) presented at the American College of Gastroenterology annual meeting found that once-daily tegoprazan significantly outperformed placebo in reducing heartburn frequency, with benefits seen for both daytime and nighttime symptoms. A new drug application for tegoprazan was submitted to the FDA in January.
A separate smaller trial in Latin American adults with erosive esophagitis found that while tegoprazan didn't significantly outperform the standard PPI pantoprazole in healing esophageal damage at 4 weeks, it delivered dramatically faster symptom relief — with 84.4% of tegoprazan patients achieving at least 50% symptom improvement in the first week, compared to just 31.3% on pantoprazole.
GERD affects up to 20% of U.S. adults, and many patients remain poorly controlled on existing therapies. Tegoprazan's rapid onset — achieving stomach pH above 4 within 45 minutes — and consistent acid control could offer a meaningful upgrade, especially for the large subset of patients who don't respond well to PPIs.
